AI drug discovery tools carry risky contract terms as USPTO inventorship rules change

Sep 28, 2026 · Issue 9 · 4 sources, 4 articles

One analysis finds that AI tools speeding up drug discovery come with risky contractual terms. A separate article discusses patent and trade secret strategy for AI drug discovery in light of the USPTO's inventorship rules.

Who is affected and how

pharmaceuticals

AI vendor contracts and the handling of inventorship rights must undergo legal review.

Sources

• The AI Tools Speeding Up Drug Discovery Come With Risky Fine Printfoley hoag · Oct 1, 2026
• The AI Tools Speeding Up Drug Discovery Come With Risky Fine Print | Foley Hoag LLPfoleyhoag.com · Oct 1, 2026
• AI Drug Discovery and USPTO Inventorship Updates: Patent and Trade Secret Strategycrowell & moring llp · Sep 28, 2026
• AI Drug Discovery and USPTO Inventorship Updates: Patent and Trade Secret Strategy | Crowell & Moring | Crowell & Moring LLPcrowell.com · Sep 28, 2026

Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.